• Zentalis appointed Shannon Campbell to its board, strengthening commercial leadership as it advances azenosertib toward late-stage ovarian cancer readouts.
• Campbell was EVP and chief commercial officer at Merus; previously held senior oncology commercial roles at Novartis and Bayer.
• Sarah Kelly joined as SVP of commercial strategy to lead launch readiness for azenosertib.
• Kelly previously held senior commercial and business development roles at Amgen, Turning Point, Spectrum, and Agilent.
• Moves align with a year-end 2026 DENALI Phase 2 topline readout; ASPENOVA Phase 3 confirmatory trial has dosed its first patient.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605271605PRIMZONEFULLFEED9727653) on May 27, 2026, and is solely responsible for the information contained therein.